Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Governance document

Draft policy on the register of members and reviewers

Consultation on the policy governing the public register of Institute members, reviewers, correspondents and contributors: who appears, what is published about each, and what is not. The draft publishes affiliation and declared interests for every member of…

Document identifier
CEI-CP-021
Series
Public comment period
Version
1.0
Published
10 Jul 2024
Last reviewed
10 Jul 2024
Next review
10 Jul 2025
Identifier
10.71829/cei.cp.21
Certainty
Not rated
Cycle
2024 Q2
Window
01 May 2024 – 30 Jun 2024
Status
Closed
Submissions
13

§1Consultation and window

§1.1Window

Opened
1 May 2024
Closed
30 June 2024
Duration
60 days
Status
Closed — the disposition is published
Document under consultation
Governance document
Submissions received
13

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the asymmetry between principals and the wider register defensible, or should the same fields be published for everyone?
  2. Should a reviewer be named against the specific document reviewed, or listed only as a member of the reviewer register?
  3. Is consent to publication obtained at the right point, and is the position clear for a person who later withdraws it?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The policy was ratified with amendments. A reviewer is named against the document reviewed where the reviewer consents and as a register member otherwise, and the position on withdrawal of consent is now stated explicitly rather than left to be inferred.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.